OPERATING ACTIVITIES
Net loss and comprehensive loss for the
period (1,682,729) (1,589,195)
Add items not involving cash
Amortization 22,363 41,380
Stock-based compensation costs included in:
Research and development expense 37,775 32,097
General and administration expense 75,015 57,293
Imputed interest on long-term debt 290,279 248,346
Accrued interest on debenture 6,779 -
Interest on convertible debentures paid
in common shares 167,218 136,944
Loss (gain) on foreign exchange 281,222 (83,553)
Net change in non-cash working capital
balances related to operations (111,451) (1,021,467)
Decrease in deferred revenue (26,670) -
-------------------------------------------------------------------------
Cash used in operating activities (940,199) (2,178,155)
-------------------------------------------------------------------------
INVESTING ACTIVITIES
Short-term investments 445,372 1,817,691
Proceeds from sale of capital assets - 873
Purchase of capital assets (9,161) (1,749)
-------------------------------------------------------------------------
Cash provided by investing activities 436,211 1,816,815
-------------------------------------------------------------------------
FINANCING ACTIVITIES
Issuance of debentures, net of issue costs 1,153,512 -
Issuance of capital stock, net of issue costs - 3,779,721
'/>"/>
| SOURCE PreMD Inc. Copyright©2008 PR Newswire. All rights reserved |